History

Dr Fernand Labrie's main milestones and highlights of EndoResearch and EndoCeuticsTM since 1957. 

 

1957-1966 :

After finishing first of all colleges affiliated to Laval University, of the province of Quebec, Dr. Fernand Labrie obtains his M.D. (magna cum laude) and then his Ph. D. in Endocrinology (summa cum laude) at Laval University in Quebec City, Canada.

1966- 1969:

He pursues his postdoctoral research training at the University of Cambridge in England, first under the direction of Professor Asher Korner, Department of Biochemistry, before joining the Laboratory of Molecular Biology under the direction of Professor Frederick Sanger, twice Nobel laureate in Medicine.

1969: 

Dr. Labrie joins the Department of Physiology at Laval University where he founded the Laboratory of Molecular Endocrinology. This laboratory then became the largest research group at Laval University and one of the largest and most renowned research groups in endocrinology on the international scene.

1973:

Dr. Labrie is the founder of the Research Group in Molecular Endocrinology of the Medical Research Council of Canada, the first group in endocrinology financed in Canada by this national agency. This internationally recognized team included up to over 350 scientists, research professionals and technicians at the cutting edge of this highly competitive field of biomedical research.

1979:

Dr. Labrie and his team discovered that chronic administration of GnRH (Gonadotropin-Releasing Hormone) agonists in men induces medical castration. GnRH agonists were found to have an efficacy equivalent to surgical castration. However, they are much better accepted than surgery, thus permitting their generalized use, especially in localized prostate cancer where many years of treatment are needed. In 1979, the first prostate cancer patient was treated with a GnRH agonist in Quebec City. Rapidly thereafter, GnRH agonists replaced surgical castration worldwide.

1982:

Soon afterwards, Dr. Labrie and his group discovered that up to 50% of androgens are left in the prostate after medical castration. He then invented combined androgen blockade which combines, at start of treatment, an antiandrogen to block the action of the androgens made locally in the prostate at the same time as testicular androgen secretion is eliminated by GnRH agonists or surgical castration. This has been the first treatment shown to prolong life in prostate cancer and it became the standard treatment worldwide.

1982:

Dr. Labrie becomes Director of Research at the Laval University Hospital Research Center. With more than 1200 high-technology employees, its five successive constructions leading to 300,000 square feet of research space, its 80 million $ state-of-the-art equipment and its annual budget of over 65 million $ in grants, awards and research contracts, the CHUL Research Center was to become, in 1996, under the direction of Dr. Labrie, among the largest Canadian medical research institutes.

1983:

Highly motivated by the success of combined androgen blockade, Dr. Labrie extends his research interests to DHEA. He then realized that after menopause, the only source of sex steroids (androgens and estrogens) is DHEA, which markedly decreases with age. In men, as mentioned above, approximately 50% of androgens originate from DHEA.

1988:

In the field of breast cancer, based upon a successful fundamental research program on the molecular biology of the intracrine enzymes with Dr. Van Luu-The and preclinical models with Dr. Jacques Simard, Dr. Labrie and his group discover and develop Acolbifene, the most potent and pure antiestrogen available for the treatment and prevention of breast and uterine cancer.

1991:

Dr. Labrie's team called this new field of medical knowledge intracrinology in 1991. This new scientific discipline has major implications for the improved therapy of hormone-sensitive diseases, especially prostate and breast cancer as well as menopause and osteoporosis.

2005:

Dr Labrie’s team with Dr. Alain Bélanger develops mass spectrometry-based steroid assays which replaced ratioimmunoassays.

2006:

In 2006, Dr. Labrie funds EndoCeuticsTM, a biopharma company centered on late stage clinical development of compounds discovered by EndoResearch. This company, operating in the field of women’s health, is focused on developing non estrogen-based therapies for vulvovaginal atrophy, sexual dysfunction and the other problems of menopause. EndoCeuticsTM' interests also include hormone therapy for Breast and Prostate Cancer as well as endometriosis and male hypogonadism. EndoCeuticsTM has 5 leading products in Phase III development, namely Intrarosaä for sexual dysfunction, the combination of DHEA with acolbifene, for the other problems of menopause and acolbifene for the prevention and treatment of breast cancer as well as compounds for endometriosis and male hypogonadism.

2009:

Dr. Labrie develops an Analytical and Bioanalytical services center within EndoCeuticsTM. This laboratory offers high-throughput, high-quality analytical and bio-analytical services to the biopharmaceutical industry, research organizations and academic institutions.

2016:

Dr. Labrie and his team provide the first scientifically and clinically proven evidence of the efficacy of Prasterone (DHEA) as replacement therapy at menopause. This demonstration pertains to intravaginal DHEA for the treatment of dyspareunia, a symptom of vulvovaginal atrophy due to menopause (Intrarosaä)

Nov 2016:

Acceptance by the US FDA of Intrarosaä for the treatment of dyspareunia, a symptom of vulvovaginal atrophy due to menopause.